SITC Archive Library

The Society for Immunotherapy of Cancer (SITC) hosted "State-of-the-Art Immunotherapies: Challenges and Opportunities" during the SITC 31st Annual Meeting & Associated Programs on November 11-13, 2016. Available here are the presentation slides and video from this program.

Session Co-Chairs

• James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
• Roy S. Herbst, MD, PhD – Yale Cancer Center

SITC 31st Annual Meeting Organizers

• Chair: Lisa H. Butterfield, PhD – University of Pittsburgh
• James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
• Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute
• Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
• Holbrook E. Kohrt, MD, PhD – Stanford Cancer Institute

Program Summary

Immunotherapy has demonstrated activity in almost every tumor type tested, changing the way cancer is treated throughout the world. However, not all patients benefit, and the search for predictive markers of response and mechanisms of resistance will be a major challenge over the next few years. In addition, with a host of new targets and drugs, the rational combination of immuno- oncology agents will be critical. This session explored opportunities from lab to clinic to better use and evaluate these promising agents.

About the SITC 31st Annual Meeting

SITC's 31st Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important Society projects. Following SITC’s tradition of collaborating to advance the field, the 31st Annual Meeting featured numerous sessions collaboratively-developed with reputable organizations whose missions complement and align with that of SITC’s. An in-depth Value of Cancer Immunotherapy Summit, organized in collaboration with the American Society of Clinical Oncology, was prominently featured to discuss a crucial topic that impacts all cancer immunotherapy constituents, from researchers and clinicians to payers and cancer patients.

Intended Audience

The intended audience for this program includes U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, scroll down to view Related Entries and Links.

#Oncologist#Researcher#AnnualMeeting#HematologicMalignancies
#ProstateCancer#Video#2016#PresentationSlides#Clinician#Biomarkers
#ClinicalTrials#Lymphoma#NonSmallCellLungCancer#Melanoma#SITC
#Cytokines#CombinationTherapy#Durvalumab#Ipilimumab#Nivolumab
#Pembrolizumab#Vaccines#AdverseEvents#Industry